Lone Star State Showcases Thriving Life Sciences Industry at World’s Largest Biotechnology Conference
AUSTIN, Texas, June 19, 2017 /PRNewswire/ — Texas is headed to San Diego this week to showcase the state’s thriving biotechnology and life sciences sector at the world’s largest biotechnology conference, BIO International. More than 16,000 biotechnology and pharmaceutical leaders are expected to attend the annual conference.
Home to approximately 4,000 life science and research firms, and 100,000 workers in related fields, Texas is fast becoming “big in biotech” as it has generated groundbreaking discoveries in medical research, pharmaceutical development and treatment innovation. Dozens of global life sciences companies, such as Novartis, Abbott, Medtronic, McKesson, Galderma, Allergan and Monsanto, have major operations in the Lone Star State.
Led by Texas Secretary of State Rolando B. Pablos and organized by Texas Economic Development Corporation (TxEDC) in partnership with the Office of Governor Greg Abbott and Texas Healthcare and Bioscience Institute (THBI), the Texas delegation includes the Cancer Prevention & Research Institute of Texas (CPRIT), 15 life sciences businesses and economic development organizations from across the state.
“BIO offers Texas a world stage to showcase our well-rounded strengths in health science, from our top-ranked workforce and business climate to our extensive R&D initiatives and breakthrough medical school programs,” said Robert Allen, President and CEO of TxEDC. “Texas has become a very big player in this industry.”
Just last month, for instance, the $310 million Dell Seton Medical Center at UT Austin opened its doors, anchoring a new healthcare innovation zone in downtown Austin. Dell Seton will serve as the primary teaching hospital for Dell Medical School—the first medical training institution in nearly 50 years to be built from the ground up at a top-tier U.S. research university.
Texas Medical Center, the world’s largest medical center, is also expanding its footprint in Texas with a 28-acre TMC3 translational research campus that will add to its existing campus by almost a third and bring together four of Texas’ most powerful institutions—the University of Texas, Texas A&M, Baylor College of Medicine and the University of Texas M.D. Anderson Cancer Center, which ranks No. 1 for cancer care by the U.S. News & World Report’s annual “Best Hospitals” survey.
Texas biotech and life sciences companies participating in the BioTexas Pavilion (Booth #427) include Lab7 Systems, Inc.; Castle Biosciences, Inc.; StemBioSysm, Inc.; OriGen Biomedical; PROLIM; TRI Air Testing; Optologix; Cible; Exegete Healthcare International; Wound Management Technologies; MANS Distributors, Inc.; Bracane Company; Fannin Innovation; American Biochemicals; and HealthBot.
About Texas Economic Development Corporation
Texas Economic Development Corporation is an independently funded and operated 501(c)(3) nonprofit organization, whose mission is dedicated to economic development, business recruitment and job creation in the State of Texas. The public-private partnership coordinates efforts with the Office of the Governor to market Texas globally as a premier business destination. For more information about Texas Economic Development Corporation, visit www.texaswideopenforbusiness.com.
SOURCE Texas Economic Development Corporation
The Bioinformatics Analyst will perform a variety of assignments within an operations and services environment.
*** BS or MS in Biology, Chemistry, or Bioinformatics, or equivalent experience
*** Must […
[Updated 6/19/17 1:17 pm. See below.] The San Diego biotech company Synthetic Genomics and supermajor ExxonMobil (NYSE: XOM) said today they have successfully inserted a gene in a particular strain…
[[Click headline to continue reading.]]
Complementary Preclinical Studies Published in Neuro-Oncology Demonstrate Immune Activation Mechanism of Tocagen’s Toca 511 & Toca FC
Increased immune infiltrates in tumor demonstratedLong-term survival and anti-tumor immune effects shown to be T cell-dependent and correlate with depletion of immune-suppressive myeloid cells
SAN DIEGO, June 19, 2017 /PRNewswire/ — Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced the publication of preclinical data in Neuro-Oncology from two independent research programs which together detail proposed mechanisms of action for Toca 511 & Toca FC involving direct tumor killing and activation of the immune system against cancer cells. The papers were published in the July issue of Neuro-Oncology, which appeared in print on June 16, 2017, and were featured on the cover and highlighted in an editorial. The articles first appeared online on April 6, 2017.
In the article titled, “Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable anti-tumor immunity in a mouse glioma model,” Mitchell, et al., monitored and characterized immune cell populations in the tumor microenvironment in mouse models of brain cancer over the course of treatment with Toca 511 and 5-FC, the active component of the Toca FC tablets used in humans. Results showed treatment-induced loss of immune cell subsets that have been shown to contribute to the suppression of normal immune activity against cancer cells, including reduction of tumor associated macrophages, myeloid-derived suppressor cells and tumor associated monocytes. Depletion of immune-suppressive myeloid cells was followed by increases in CD4+ and CD8+ T cells which correlated with tumor reduction. Mice that cleared tumors following treatment with Toca 511 and 5-FC were protected against re-challenge with the same tumor type. Furthermore, successful adoptive cell transfer experiments using isolated immune cells from successfully treated animals confirmed anti-tumor immune responses were T cell-dependent.
In the article titled, “Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anti-cancer immunity,” Hiraoka and Inagaki, et al., performed molecular imaging of immune-deficient and immune-competent mouse models of brain cancer following treatment with Toca 511 and cycles of 5-FC. These studies were performed in the laboratory of Noriyuki Kasahara, M.D., Ph.D., professor of cell biology and pathology at the University of Miami. While long-term survival benefit was seen in both models, tumor was undetectable in immune-competent mice after three cycles of 5-FC. In contrast, immune-deficient mice required continuous treatment with cycles of 5-FC for long-term survival benefit, and tumor recurrence was still evident between cycles. After clearance of tumors in immune-competent mice by treatment with Toca 511 and 5-FC, long-term protection against future challenge with the same tumor type was seen. Long-term immune memory against the tumor was lost upon depletion of T cell subsets, indicating a T cell-dependent anti-tumor immune response.
The complementary findings reported in these publications demonstrate that anti-tumor immune effects are T-cell dependent and correlate with depletion of immune-suppressive myeloid cells.
Toca 511 & Toca FC is in clinical development for the treatment of recurrent high grade glioma, or HGG, a type of brain cancer. Tocagen has completed enrollment of the Phase 2 portion of a Phase 2/3 clinical trial and plans to report top-line results of the study in the first half of 2018. The U.S. Food and Drug Administration (FDA) granted Toca 511 & Toca FC Breakthrough Therapy Designation for the treatment of patients with recurrent HGG.
Research reported in the publication by Hiraoka and Inagaki, et al. was supported in part by the National Institute of Neurological Diseases and Stroke (NINDS) in the National Institutes of Health (NIH) under award number U01NS059821. The content is solely the responsibility of the authors and does not necessarily represent the official views of NINDS or NIH.
Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer. Tocagen is developing its lead investigational product candidate, Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma (HGG), a disease with significant unmet medical need. Toca 511 & Toca FC was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of recurrent HGG. Tocagen has received grant support from leading brain cancer foundations, including Accelerate Brain Cancer Cure (ABC2), National Brain Tumor Society (NBTS), American Brain Tumor Association (ABTA), Musella Foundation and Voices Against Brain Cancer (VABC). For more information, visit www.tocagen.com or follow @Tocagen.
SOURCE Tocagen Inc.
FDA Accepts Rigel’s New Drug Application for TAVALISSE(TM) (fostamatinib disodium) for the Treatment of Chronic ITP
SOUTH SAN FRANCISCO, Calif., June 19, 2017 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced the U.S. Food and Drug Administration (FDA) has filed its New Drug Application (NDA) for the use of TAVALISSE™ (fostamatinib disodium) in patients with chronic or persistent immune thrombocytopenia (ITP). Rigel expects the action date for the FDA to complete its review will be April 17, 2018, under the Prescription Drug User Fee Act (PDUFA). The FDA previously granted Orphan Drug designation to TAVALISSE™ for the treatment of patients with ITP.
“The FDA acceptance for filing of our NDA is an exciting milestone for Rigel,” said Raul Rodriguez, Rigel’s president and chief executive officer. “If approved, we believe TAVALISSE™ will provide a new treatment option for patients with chronic or persistent ITP. We look forward to working closely with the FDA as they review our submission.”
The NDA submission is supported by data from the Phase 3 clinical program for fostamatinib in ITP, which was comprised of three studies, two randomized placebo-controlled studies (Studies 047 and 048), and an open-label extension study (Study 049). Together with an initial proof of concept study, the NDA included 163 ITP patients. Across all indications, fostamatinib has been evaluated in over 4,600 subjects. Data from all studies, including preclinical evaluation and drug manufacturing data, were included in the NDA submission.
In patients with ITP, the immune system attacks and destroys the body’s own blood platelets, which play an active role in blood clotting and healing. Common symptoms of ITP are excessive bruising and bleeding. People suffering with chronic ITP may live with increased risk of severe bleeding events that can result in serious medical complication, or even death. Currently approved therapies for ITP include steroids, blood platelet production boosters (TPO-RAs) and splenectomy. However, not all patients derive a benefit from existing therapies. As a result, there remains a significant medical need for additional treatment options for patients with ITP.
About TAVALISSE™ (fostamatinib disodium)
TAVALISSE™ is an oral investigational drug candidate designed to inhibit SYK kinase, a key signaling member in the immune process that leads to platelet destruction in ITP. Unlike other therapies that modulate the immune system in different ways or stimulate platelet production, fostamatinib may address an underlying autoimmune cause of ITP by impeding platelet destruction.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases. Rigel’s pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company’s current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. Rigel has submitted an NDA to the FDA for fostamatinib in patients with chronic or persistent immune thrombocytopenia (ITP). In addition, Rigel has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics.
Forward Looking Statements
This release contains forward-looking statements relating to, among other things, the timing of a response from the FDA to our NDA submission and Rigel’s belief that fostamatinib may be an attractive alternative for patients with ITP. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “if,” “planned,” “will,” “may,” “expect,” and similar expressions are intended to identify these forward-looking statements. These forward-looking statements are based on Rigel’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, the FDA may interpret Rigel’s findings differently, which could result in the FDA not approving any submitted NDA; the availability of resources to develop Rigel’s product candidates; Rigel’s need for additional capital in the future to sufficiently fund Rigel’s operations and research; the uncertain timing of completion of and the success of clinical studies; market competition, risks associated with and Rigel’s dependence on Rigel’s corporate partnerships; risks related to changes in estimated cash position based on the completion of financial closing procedures and the audit of Rigel’s financial statements; as well as other risks detailed from time to time in Rigel’s reports filed with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2017. Rigel does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.
Contact: Raul Rodriguez
Media Contact: Jessica Daitch
SOURCE Rigel Pharmaceuticals, Inc.
VP, Biologics Research (Discovery Head), Janssen Biotherapeutics – Johnson & Johnson Family of Companies – La Jolla, CA
Biotechnology strategy and direction. Biotechnology drugs through the pipeline. Cross-functional coordination in elevating our biotechnology efforts….
From Johnson & Johnson Family of Companies – Mon, 19 Jun 2017 10:47:34 GMT – View all La Jolla, CA jobs
The successful candidate must excel in communication, have strong interpersonal skills necessary to influence in a team setting, and ideally have leadership…
From Johnson & Johnson Family of Companies – Mon, 19 Jun 2017 10:47:07 GMT – View all San Diego, CA jobs
Implemented intern program with local university as appointed program manager; A Bachelor’s Degree, along with 5 or more years of office management experience….
From Johnson & Johnson Family of Companies – Mon, 19 Jun 2017 10:47:06 GMT – View all San Diego, CA jobs
Tessa Therapeutics and Parker Institute for Cancer Immunotherapy Enter into Strategic Alliance Agreement
Unique collaboration model will leverage the Parker Institute’s immunotherapy network and Tessa’s Virus Specific T Cell (VST) platform to create next generation cancer immunotherapy treatmentsTessa Therapeutics is the first cellular therapy partner company to form a multi-year alliance with the Parker Institute
SINGAPORE and SAN FRANCISCO, June 19, 2017 /PRNewswire-USNewswire/ — Tessa Therapeutics (Tessa) and the Parker Institute for Cancer Immunotherapy (Parker Institute) today announced the establishment of a multi-year strategic alliance to combine their capabilities to jointly advance research in the field of cancer immunotherapy. The two partners will collaborate on unique clinical and pre-clinical projects in order to develop novel cellular therapy and immuno-oncology combination treatments.
The Parker Institute’s model brings together top cancer research institutions to share resources, data, and technology, accelerate research through unifying and managing clinical trial design, and conduct multi-center clinical trials. Tessa brings its T cell therapy expertise to the partnership. Tessa’s Virus Specific T Cell technology holds the promise of becoming a treatment platform for a wide variety of cancer indications and the company’s international production and logistics network enables the rapid roll-out of large-scale, multi-center cellular therapy trials. Tessa is currently conducting the world’s first FDA Phase III cancer T cell therapy trial.
This is the Parker Institute’s first major agreement with a cellular therapy partner. The Parker Institute will continue to build key industry relationships critical for the success of its unique model.
Fred Ramsdell, Ph.D., Vice President of Research at the Parker Institute, said, “Tessa has built both an impressive team as well as a very advanced suite of capabilities in the immuno-oncology realm. They have recognized many of the challenges to cellular therapies and are addressing them in thoughtful and science driven ways – and laying the foundation for the next generation of therapies. Few organizations have the commitment and vision of Tessa, and we are excited to help bring these attributes to our Parker Institute network and to further the goal of effective therapeutic development.”
Andrew Khoo, co-founder and CEO of Tessa Therapeutics, said, “The Parker Institute is driving innovation in the field of cancer immunotherapy by bringing together the best immunologists, cancer research institutes, and industry partners globally. We feel a strong sense of alignment in terms of our vision and ultimate goals. At Tessa, we are excited to join this network and together leverage our strong translational capabilities to build further on Tessa’s core VST platform. As a partner of the Parker Institute and a member of the Institute-led consortium, we are committed to a range of exciting collaborative projects, working towards our shared vision of a world without untreatable cancers.”
John E. Connolly, Chief Scientific Officer of Tessa Therapeutics, added, “The Parker Institute enables a first-of-its-kind model for collaboration among world-leading academic and industry partners to accelerate research into innovative cancer immunotherapies. We are delighted to be their first cell therapy partner and look forward to leveraging on the Institute’s hub and spoke model for collaborative studies to design next-generation immunotherapeutic technologies and to translate research into treatments that will transform patients’ lives for the better.”
About Tessa Therapeutics
Tessa Therapeutics is a fully-integrated, international biotech company with the scientific vision of revolutionizing the treatment of cancer by redirecting the body’s potent anti-viral immune response to recognize and kill cancer cells. Tessa’s core virus-specific T cell (VST) platform has shown compelling results in the treatment of solid tumors, and the company is building a portfolio of therapies addressing a wide range of tumors by combining the qualities of its T cell platform with complementary technologies. Tessa’s lead Phase III trial for Nasopharyngeal carcinoma (NPC) is the world’s largest Phase III T Cell immunotherapy trial for any cancer indication. The company has built up robust operational and supply chain capabilities to successfully deliver autologous T cell therapy treatments to a large patient pool across five countries. Tessa has exclusive licenses to multiple technologies developed at Baylor College of Medicine. The National Cancer Centre Singapore, one of Asia’s leading clinical research centers, is a strategic shareholder of Tessa and has granted exclusive rights to immuno-oncology technologies to Tessa. The combination of such technologies from its academic, clinical, and commercial research partners have enabled the company to create a fully-integrated approach to the treatment of cancer with immunotherapy.
For more information on Tessa, please visit www.tessatherapeutics.com.
About Parker Institute for Cancer Immunotherapy
The Parker Institute for Cancer Immunotherapy brings together the best scientists, clinicians and industry partners to build a smarter and more coordinated cancer immunotherapy research effort. The Parker Institute is an unprecedented collaboration between the country’s leading immunologists and cancer centers, including Memorial Sloan Kettering Cancer Center, Stanford Medicine, the University of California, Los Angeles, the University of California, San Francisco, the University of Pennsylvania and The University of Texas MD Anderson Cancer Center. The Parker Institute network also includes more than 40 industry and nonprofit partners, more than 60 labs and more than 300 of the nation’s top researchers focused on treating the deadliest cancers.
The goal is to accelerate the development of breakthrough immune therapies capable of turning most cancers into curable diseases. The Institute was created through a $250 million grant from The Parker Foundation.
For more information, visit www.parkerici.org.
This press release may contain forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements, and past performance should not be considered as an indication of future performance.
SOURCE Tessa Therapeutics
Informa’s Business Intelligence (BI) division, part of the FTSE 100 Informa Group, provides specialist data, intelligence and insight to our customers, helping…
From Informa Business Intelligence – Mon, 19 Jun 2017 07:55:18 GMT – View all San Diego, CA jobs